Fred, I spoke to the CEO last night to express
Post# of 9122
(Total Views: 601)
Posted On: 05/01/2019 8:47:59 AM
Fred,
I spoke to the CEO last night to express my excitement at the release. None of what follows or what was stated from that conversation is anything other than general publicly available information.
The pre-test is apparently an initial diagnostic that MDs said they want to have. It makes sense. The lateral flow aspect, which is the same technology used in positive/negative home pregnancy tests, should allow for indication of bacteria “presence” above a certain concentration in a few minutes. Ideally the same sample would be applied to their N-Assay and within hours that would then provide all the complex information on severity (optical density data from N-Assay plate reader colorimetric data) aka concentration of bacteria and its associated antibiotic sensitivity. That data allows a rapid informed decision on treatment using the proper course of antibiotics rather than an initial use of broad-spectrum antibiotics which could contribute to more of the critically noted antibiotic resistance problem that exists.
As for the importance of what was stated in the PowerPoint presentation they posted yesterday,
what part of moving from the N-Assay diagnostic test for UTI as presented in the earlier update a month or so back, to revealing its utility for URI and variants on Sepsis isn’t obvious? What if that diagnostic reduced annual Sepsis deaths from 250,000 to 200,000 or 100,000?
That FaceBook site has nothing to do with anything official from NanoLogix, it appears to be something a shareholder has done.
Scott
I spoke to the CEO last night to express my excitement at the release. None of what follows or what was stated from that conversation is anything other than general publicly available information.
The pre-test is apparently an initial diagnostic that MDs said they want to have. It makes sense. The lateral flow aspect, which is the same technology used in positive/negative home pregnancy tests, should allow for indication of bacteria “presence” above a certain concentration in a few minutes. Ideally the same sample would be applied to their N-Assay and within hours that would then provide all the complex information on severity (optical density data from N-Assay plate reader colorimetric data) aka concentration of bacteria and its associated antibiotic sensitivity. That data allows a rapid informed decision on treatment using the proper course of antibiotics rather than an initial use of broad-spectrum antibiotics which could contribute to more of the critically noted antibiotic resistance problem that exists.
As for the importance of what was stated in the PowerPoint presentation they posted yesterday,
what part of moving from the N-Assay diagnostic test for UTI as presented in the earlier update a month or so back, to revealing its utility for URI and variants on Sepsis isn’t obvious? What if that diagnostic reduced annual Sepsis deaths from 250,000 to 200,000 or 100,000?
That FaceBook site has nothing to do with anything official from NanoLogix, it appears to be something a shareholder has done.
Scott
(6)
(0)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼